Tomligisiran (sodium)
Tomligisiran sodium is a siRNA in JNJ-3989 (JNJ-73763989) . JNJ-3989 is comprised of 2 siRNAs (Daplusiran and Tomligisiran), that target hepatitis B virus (HBV) mRNAs for degradation, thereby inhibiting HBV replication.
Product Specifications
UNSPSC
12352208
Target
HBV
Related Pathways
Anti-infection
Applications
COVID-19-anti-virus
Field of Research
Infection
Smiles
[Tomligisiran(sodium)]
References & Citations
[1]Kakuda TN, Halabi A, Klein G, et al. Pharmacokinetics of JNJ-73763989 and JNJ-56136379 (Bersacapavir) in Participants With Moderate Hepatic Impairment. J Clin Pharmacol. 2023;63 (6) :732-741.|[2]Li H, Niu X, Zhang Y, et al. Pharmacokinetics, Safety, and Tolerability of the siRNA JNJ-73763989 in Healthy Chinese Adult Participants. Clin Pharmacol Drug Dev. 2023;12 (2) :175-180.|[3]Gane E, Yuen MF, Kakuda TN, et al. JNJ-73763989 pharmacokinetics and safety: Liver-targeted siRNAs against hepatitis B virus, in Japanese and non-Japanese healthy adults, and combined with JNJ-56136379 and a nucleos (t) ide analogue in patients with chronic hepatitis B. Antivir Ther. 2022;27 (3) :13596535221093856.
Shipping Conditions
Room temperature
Scientific Category
Oligonucleotides
Clinical Information
Phase 2
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
GTR15208463 1 Vial
Lentiviral mouse Hoxa13 shRNA (UAS) - Lentiviral mouse Hoxa13 shRNA (UAS, RFP) (25)
Ask
View Details 
MBS1376263-01 0.02 mg (E-Coli)
Recombinant Staphylococcus aureus Uncharacterized peptidase SAB1567 (SAB1567)
Ask
View Details MBS1376263-02 0.02 mg (Yeast)
Recombinant Staphylococcus aureus Uncharacterized peptidase SAB1567 (SAB1567)
Ask
View Details MBS1376263-03 0.1 mg (E-Coli)
Recombinant Staphylococcus aureus Uncharacterized peptidase SAB1567 (SAB1567)
Ask
View Details